Oramed Pharmaceuticals Inc. — Director's Dealing 2017

Aug 17, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2017-08-15

Reporting Person: Sank Leonard (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-15	Common Stock	M	11262	$6.00	Acquired	282158	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-15	Warrant (right to buy)	$6.00	M	11262	Disposed	2017-08-15	Common Stock (11262)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	78125	Indirect
Common Stock	138889	Indirect

Footnotes

F1: Mr. Sank disclaims beneficial ownership of these shares.

F2: These shares consist of shares of common stock owned by a company wholly owned by a trust of which Mr. Sank is a trustee. Mr. Sank disclaims beneficial ownership of these shares.

F3: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.

F4: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.